NEWS AND EVENTS
KEEP IN TOUCH WITH US
25 Apr
2019

A*Star unit in $122m deal to co-create deep-tech start-ups

<The Straits Times>

The enterprise arm of the Agency for Science, Technology and Research (A*Star) has signed a US$90 million (S$122 million) agreement to co-create local deep-tech start-ups in healthcare and life sciences.

The agreement between A*ccelerate Technologies, Nasdaq-listed pharmaceutical firm Aptorum Group and Hong Kong financial institution Aeneas Capital aims to create up to 20 deep-tech ventures in Singapore over the next five years.

These start-ups will tap technologies co-developed by A*Star research institutes and Aptorum, and will get help with being connected to market partners and clients via Aptorum's global network.

One area being explored is imaging solutions in surgical robotics. This would involve applying A*Star's capabilities in medical image analytics and augmented reality to real-time 2D and 3D magnetic resonance imaging surgical imaging solutions.

A*ccelerate chief executive Philip Lim said: "This agreement is testament to the vibrancy of Singapore's biotech ecosystem, as well as the private sector's confidence in A*Star's capabilities in deep-tech and biomedical research."

Mr Ian Huen, founder and chief executive officer of Aptorum and the founder of Aeneas Capital, believes the partnership will yield "strong venture businesses that will be eventually recognised worldwide".

Separately, Aptorum and Aeneas Capital will launch a healthcare and life science strategic investment fund of up to US$200 million, which might invest in the local biotech ecosystem.

The two parties will also make acquisitions in identified technologies and businesses globally.

The agreement between A*ccelerate, Nasdaq-listed pharmaceutical firm Aptorum Group and Hong Kong financial institution Aeneas Capital aims to create up to 20 deep-tech ventures in Singapore over the next five years. These start-ups will tap technologies co-developed by A*Star research institutes and Aptorum, and will get help with being connected to market partners and clients via Aptorum's global network.

(Source: https://www.straitstimes.com/business/invest/astar-unit-in-122m-deal-to-co-create-deep-tech-start-ups)

25 Apr
2019

Nasdaq-listed biotechnology Aptorum partner with Singapore technology agency invest in 20 companies

<Ming Pao>
(Chinese printed version only)

【明報專訊】去年12月在美國納斯達克上市的本地製藥企業知臨集團昨日宣布,與新加坡科技研究局子公司A*ccelerate達到共9000萬美元的合作協議,冀於未來5年投資20家高科技公司在新加坡創立。知臨集團創辦人兼行政總裁禤駿遠表示,今次合作類似風險投資,他們會投資全球的初創生物科技企業,以研發不同的藥物,之後企業亦可以利用不同的融資渠道去支持自己的研發項目。

禤駿遠身兼艾納斯資本創辦人,亦與知臨及A*ccelerate發起一個2億美元的醫療基金,開放予全球投資者認購,希望年內完成第一階段募款。禤駿遠表示,基金亦會投資在上述的9000萬美元(約7.02億港元)協議,惟不願透露基金會分多少個階段完成。

創辦人禤駿遠組醫療基金

知臨集團亦有自己的科研團隊,主要模式是從香港大學及中文大學中購買研究藥物牌照,之後再自行開展臨床試驗。公司目前有11項在研藥物,當中管線最快為由港大醫學院研發的對抗金黃葡萄球菌的非抗生素藥物,禤駿遠稱應會透過美國藥監局去申請全球性的臨牀測試,可望年內開展。

知臨總部處科學園

擁11項在研藥物

集團目前總部設於香港科學園,科研團隊約有80人,另外在北美及加拿大有長期合作的實驗室,協助進行臨牀測試。作為香港公司,卻選擇赴美上市,禤駿遠表示,由於公司不少產品都透過美國藥監局申請臨牀試驗,而且上市計劃已在香港上市改革公布前進行,惟強調「絕對有可能」來港作雙重上市,亦與聯交所及投資持續者商討,惟未有確實時間表,並指公司規模距離聯交所的門檻仍有一段距離,相信仍需一段時間才可達到。

Source: https://news.mingpao.com/pns/%E7%B6%93%E6%BF%9F/article/20190425/s00004/1556130333784/%E7%BE%8E%E4%B8%8A%E5%B8%82%E7%94%9F%E7%A7%91%E8%82%A1%E7%9F%A5%E8%87%A8-%E4%BC%99%E6%98%9F%E7%A0%94%E7%A9%B6%E5%B1%80%E6%8A%95%E8%B3%8720%E4%BC%81

25 Apr
2019

Why this Nasdaq-listed Company Wants to Strengthen the Singaporean Startup Ecosystem

<Entrepreneur>

Nasdaq-listed Aptorum Group has inked a deal of US$90 million with Accelerate Technologies to co-create deep tech startups in the healthcare and life sciences sectors. The agreement comes as a latest move in the venture co-creation to strengthen the startup ecosystem in Singapore.

Deep Tech – a New Fad

Both the companies are looking at creating up to 20 deep tech ventures in Singapore over the next five years, says the company in its statement to the press. These enterprises will leverage technologies co-developed by A*STAR research institutes and Aptorum Group. As part of this agreement, the parties involved will also support the startups’ growth through actively nurturing the entrepreneurs. This will be done by connecting them to the relevant market partners and clients, using Aptorum Group’s worldwide network.

The key focus area in this initiative would be the healthcare and life sciences sectors. One of the areas both parties are looking into is the translation of A*STAR’s capabilities in medical image analytics and augmented reality, into real-time 2D and 3D magnetic resonance imaging (MRI) surgical imaging solutions for applications in the field of surgical robotics. This solution is expected to empower healthcare providers in Singapore, the region, and globally with more accurate imaging of their patients.

“This agreement is testament to the vibrancy of Singapore’s biotech ecosystem, as well as the private sector’s confidence in A*STAR’s capabilities in deep tech and biomedical research,” says Philip Lim, CEO of Accelerate.

“Aptorum Group’s focus on creating value in diagnostics, surgical robotics and therapeutics through technological innovation makes them an ideal partner for us. We look forward to co-creating local startups that will push the boundaries of healthcare innovation and strengthen Singapore’s future economy,” he adds.

Why Singapore

Aptorum Group and Aeneas Capital will also be launching an up to $200 million healthcare and life science strategic investment fund. This fund could be used to invest in the local biotech ecosystem and bring about greater vibrancy to the Singapore economy. Aptorum Group and Aeneas Capital will also make acquisitions in identified technologies and businesses globally.

Elaborating more about the partnership, founder and CEO of Aptorum Group,Ian Huen says, “Aptorum’s vision is to advance the quality of human life and patient care by facilitating the development of medical and life science innovations. Our collaboration with Accelerate venture co-creation partner is very exciting, allowing us to access and develop the excellent expertise and technological ecosystems in Singapore through a strong partner such as A*STAR and to strengthen the links between research, innovation and enterprise.”

The pharmaceutical company believes that the partnership will undoubtedly yield a number of strong venture businesses that will eventually be recognised worldwide and further catapult Singapore as a core global player for technological advancements and commercialisation hub.

Source: https://www.entrepreneur.com/article/332790

×
×
×
×
Terms of Use

This Website contains information concerning Aptorum Group Limited (“Aptorum Group”) and its affiliates that may be useful to Aptorum Group’s customers, suppliers, employees, directors and shareholders, as well as members of the general public. However, by using this Website you are accepting all of the terms of this disclaimer notice, including exclusions and limitations of liability. If you do not agree with anything in this notice, you should not use this Website.

Aptorum Group does not claim ownership of the materials and product images on the Website that are provided to us by our third party suppliers.

Where our Website contains links to other sites and resources provided by third parties, these links are provided for your information only. We have no control over the contents of those sites or resources, and accept no responsibility for them or for any loss or damage that may arise from your use of them. These links are provided solely as a convenience to you and not as an endorsement by us of the contents on such third party websites.

While reasonable efforts are made to ensure that the contents of this Website are accurate, this Website and its contents are provided on an “as is,” “as available” basis, without warranties of any kind, including any warranty that the Website will be kept up to date, be true and not misleading, or that the Website will always (or ever) be available for use. Aptorum Group and its affiliates disclaim all warranties, express or implied, with respect to the Website and its contents, including, without limitation, any warranties of accuracy, completeness, timeliness, non-infringement, title, merchantability, or fitness for a particular purpose. Because some jurisdictions do not permit the exclusion of certain warranties, these exclusions may not apply to you.

In no event will Aptorum Group or its affiliates be liable for any incidental, indirect, consequential, or special damages of any kind, or any damages whatsoever, including, without limitation, those resulting from loss of profits, contracts, goodwill, data, information, income, anticipated savings, or business relationships, whether or not Aptorum Group or its affiliates have been advised of the possibility of such damage, arising out of or in connection with the use of this Website or its contents or any other sites linked to this Website.

If you have any concerns about material which appears on our Website, please contact us. We have the right and the ability to remove immediately from our Website any material that is infringing, defamatory, offensive, abusive, harming, deceptive, threatening or otherwise illegal.